Taiwan Bio and TRACT Therapeutics announced a new strategic partnership to advance a cellular therapy to revolutionize the prevention of allograft rejection in solid organ transplant. The partners will launch a multi-center Phase 2 clinical trial investigating the reduction of immunosuppressant drugs in living donor kidney transplant recipients in both the United States and Taiwan. This partnership leverages Taiwan Bio?s world-class expertise in cellular therapy manufacturing and TRACT
Therapeutics? innovative immune modulating regulatory T cell therapy platform. By combining their strengths,
the companies are set to explore new frontiers in enabling allogeneic tissue transplant with a focus on enhanced
patient outcomes and improved quality of life. The upcoming Phase 2 trial builds upon the promising results
from a Phase 1 study which demonstrated an excellent safety profile and encouraging efficacy signals with
TRACT?s autologous Treg product, TregCelTM.